vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.6× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -127.8%, a 146.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -2.5%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $148.6M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 1.3%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
MEDP vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.1B |
| Net Profit | $135.1M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 21.6% | -116.0% |
| Net Margin | 19.1% | -127.8% |
| Revenue YoY | 32.0% | -2.5% |
| Net Profit YoY | 15.5% | -3093.9% |
| EPS (diluted) | $4.65 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.1B | ||
| Q3 25 | $659.9M | $1.0B | ||
| Q2 25 | $603.3M | $1.1B | ||
| Q1 25 | $558.6M | $1.0B | ||
| Q4 24 | $536.6M | $1.1B | ||
| Q3 24 | $533.3M | $1.1B | ||
| Q2 24 | $528.1M | $1.1B | ||
| Q1 24 | $511.0M | $1.1B |
| Q4 25 | $135.1M | $-1.4B | ||
| Q3 25 | $111.1M | $7.5M | ||
| Q2 25 | $90.3M | $-8.4M | ||
| Q1 25 | $114.6M | $-6.4M | ||
| Q4 24 | $117.0M | $-44.4M | ||
| Q3 24 | $96.4M | $-21.0M | ||
| Q2 24 | $88.4M | $-108.4M | ||
| Q1 24 | $102.6M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 21.6% | -116.0% | ||
| Q3 25 | 21.5% | 7.0% | ||
| Q2 25 | 20.9% | 4.3% | ||
| Q1 25 | 20.3% | 4.5% | ||
| Q4 24 | 23.4% | 10.0% | ||
| Q3 24 | 21.1% | 7.4% | ||
| Q2 24 | 19.9% | -2.5% | ||
| Q1 24 | 20.4% | -5.1% |
| Q4 25 | 19.1% | -127.8% | ||
| Q3 25 | 16.8% | 0.7% | ||
| Q2 25 | 15.0% | -0.8% | ||
| Q1 25 | 20.5% | -0.6% | ||
| Q4 24 | 21.8% | -3.9% | ||
| Q3 24 | 18.1% | -1.9% | ||
| Q2 24 | 16.7% | -10.2% | ||
| Q1 24 | 20.1% | 0.2% |
| Q4 25 | $4.65 | $-10.23 | ||
| Q3 25 | $3.86 | $0.05 | ||
| Q2 25 | $3.10 | $-0.06 | ||
| Q1 25 | $3.67 | $-0.05 | ||
| Q4 24 | $3.67 | $-0.32 | ||
| Q3 24 | $3.01 | $-0.15 | ||
| Q2 24 | $2.75 | $-0.79 | ||
| Q1 24 | $3.20 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $2.9B |
| Total Assets | $2.0B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | $432.1M | ||
| Q2 25 | $46.3M | $454.2M | ||
| Q1 25 | $441.4M | $409.9M | ||
| Q4 24 | $669.4M | $558.8M | ||
| Q3 24 | $656.9M | $1.5B | ||
| Q2 24 | $510.9M | $542.8M | ||
| Q1 24 | $407.0M | $658.5M |
| Q4 25 | $459.1M | $2.9B | ||
| Q3 25 | $293.6M | $4.4B | ||
| Q2 25 | $172.4M | $4.5B | ||
| Q1 25 | $593.6M | $4.4B | ||
| Q4 24 | $825.5M | $4.3B | ||
| Q3 24 | $881.4M | $4.6B | ||
| Q2 24 | $763.6M | $4.5B | ||
| Q1 24 | $671.5M | $4.7B |
| Q4 25 | $2.0B | $8.5B | ||
| Q3 25 | $1.8B | $10.1B | ||
| Q2 25 | $1.6B | $10.1B | ||
| Q1 25 | $1.9B | $9.8B | ||
| Q4 24 | $2.1B | $9.6B | ||
| Q3 24 | $2.1B | $11.2B | ||
| Q2 24 | $1.9B | $10.4B | ||
| Q1 24 | $1.8B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $175.4M |
| Free Cash FlowOCF − Capex | $188.1M | $148.6M |
| FCF MarginFCF / Revenue | 26.6% | 13.4% |
| Capex IntensityCapex / Revenue | 0.6% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $175.4M | ||
| Q3 25 | $246.2M | $51.7M | ||
| Q2 25 | $148.5M | $75.9M | ||
| Q1 25 | $125.8M | $-64.5M | ||
| Q4 24 | $190.7M | $312.6M | ||
| Q3 24 | $149.1M | $42.2M | ||
| Q2 24 | $116.4M | $9.5M | ||
| Q1 24 | $152.7M | $-1.4M |
| Q4 25 | $188.1M | $148.6M | ||
| Q3 25 | $235.5M | $29.8M | ||
| Q2 25 | $142.4M | $56.7M | ||
| Q1 25 | $115.8M | $-90.0M | ||
| Q4 24 | $183.0M | $274.9M | ||
| Q3 24 | $138.5M | $15.1M | ||
| Q2 24 | $103.5M | $-18.9M | ||
| Q1 24 | $147.2M | $-26.5M |
| Q4 25 | 26.6% | 13.4% | ||
| Q3 25 | 35.7% | 2.9% | ||
| Q2 25 | 23.6% | 5.4% | ||
| Q1 25 | 20.7% | -8.6% | ||
| Q4 24 | 34.1% | 24.2% | ||
| Q3 24 | 26.0% | 1.4% | ||
| Q2 24 | 19.6% | -1.8% | ||
| Q1 24 | 28.8% | -2.4% |
| Q4 25 | 0.6% | 2.4% | ||
| Q3 25 | 1.6% | 2.1% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.3% | ||
| Q3 24 | 2.0% | 2.5% | ||
| Q2 24 | 2.4% | 2.7% | ||
| Q1 24 | 1.1% | 2.3% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | 6.89× | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
